BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Mesoblast’s Stem Cell Therapy Shows 83% Survival in Ventilator-Dependent COVID-19 Patients

  Mesoblast announced that in a study of COVID-19 patients with moderate to severe acute respiratory distress syndrome, there was 83% survival with two intravenous infusions of the company’s experimental allogeneic mesenchymal stem cell candidate Ryoncil.

  April 24, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca and Merck’s Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations

  AstraZeneca and Merck & Co. released more positive data from the Phase III PROfound trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer.

  April 24, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Using AI to Find Peptide Therapeutics for COVID-19

  Nuritas, a biotech company that focuses on leveraging artificial intelligence (AI) to discover therapeutic peptides, is joining the fight by tasking their powerful AI platform to find peptides that can be used as therapeutics for COVID-19.

  April 24, 2020

   · 

  7 min read

   · 

  Chelsea Weidman Burke
• 

  Drug Development

  Cloned Antibodies to COVID-19 Virus Show Promise for Therapy and Prevention

  Although promising, it’s still unclear if this would actually prevent infection in people.

  April 24, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Mammoth’s CRISPR Assay for Asymptomatic COVID-19 Carriers Gains Peer-Reviewed Validation

  Following news of Mammoth Biosciences’ CRISPR diagnostic assay to detect SARS-CoV-2, the company talked at length with BioSpace about this new test and its ramifications.

  April 24, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  J&J and Emergent BioSolutions Strike Manufacturing Deal for COVID-19 Vaccine Candidate

  Less than one month after Johnson & Johnson identified a lead vaccine candidate against COVID-19, the life sciences giant announced an agreement with Emergent BioSolutions to support the manufacturing needs for the potential medication.

  April 24, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Job Trends

  Clinical Catch-Up: April 20-24

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.

  April 24, 2020

   · 

  10 min read

   · 

  Mark Terry
• 

  FDA

  FDA Approves Sanofi’s Meningococcal Meningitis Vaccine

  David Loew, head of Sanofi Pasteur, said U.S. approval of the vaccine is an important milestone in the fight against meningococcal meningitis, a serious global health challenge that can be fatal within 24 hours.

  April 24, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: April 24

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.

  April 24, 2020

   · 

  7 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Takeda and ProThera Enter Agreement to Develop Novel IAIP Therapy

  “Our goal is to successfully treat patients with severe inflammatory conditions and this is now possible through our alliance with Takeda,” said Denice Spero, president and chief business officer of ProThera.

  April 24, 2020

   · 

  3 min read

   · 

  Krystle Vermes